Novartis business deals across mergers & acquisitions, business development & licensing were summarized for investors at 2024 J.P. Morgan Healthcare conference.
This video highlights the scale and strategic focus of over $6bn of deals in 2023 by our CEO Vas Narasimhan. It provides examples of how our we are strengthening portfolios and how AI advancements in drug development moves are creating a stronger company for the future.
*This video uses audio from the webcasted event.*
J.P. Morgan Healthcare Conference
Event Date: January 08, 2024
Full webcast here: go.novartis.social/49012mq
Full presentation here: go.novartis.social/3SzISTc
Novartis JPM HC 2024 Coverage: go.novartis.social/48T3StR
Investor Relations: go.novartis.social/3SCtnKp
Investor Events: go.novartis.social/3vWoP8M
Novartis Strategy: go.novartis.social/42iv0jr
Disclaimer: J.P. Morgan Healthcare Conference live event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: go.novartis.social/3SzISTc
The J.P. Morgan Healthcare conference live event also contains non-IFRS measures. An explanation of non-IFRS measures can be found on our website go.novartis.social/4bk6cM3.
Learn more: go.novartis.social/48T3StR